

William Fulton, MD thesis, University of Glasgow 1963

# New insights from coronary physiology

## From the FFR-based deferral to the #Full Physiology Approach

**Antonio Maria Leone MD PhD**

*Director of Chronic Coronary Syndromes Program  
Department of Cardiovascular Sciences  
Fondazione Policlinico Universitario A. Gemelli IRCCS  
Roma*



# Potential conflicts of interest

**Speaker's name: Antonio Maria Leone**

 **I have the following potential conflicts of interest to report:**

Dr. A.M. Leone is an advisor for Abbott Vascular and Bracco Imaging and received speaking honoraria from Abbott Vascular, Medtronic and Abiomed in the past.


All contents provided by Dr. Leone unless otherwise noted




# How ICs think about invasive physiology

DEFER


Cardiac Death and Acute MI after 5 Years





FAME 1



FAME 2



% Patients Free from Chest Pain



		Randomised trial		Randomised trial compared to registry	
	No CCS II-IV/ No total	RR (95% CI)	P value	RR (95% CI)	P value
Baseline					
PCI+MT	314/447	1.04 (0.95-1.13)	0.42	1.09 (0.96-1.24)	0.17
MT alone	298/440	1.00 (reference)		1.05 (0.92-1.20)	0.45
Registry	107/166			1.00 (reference)	
30 Days					
PCI+MT	45/441	0.36 (0.26-0.49)	<0.001	0.66 (0.42-1.04)	0.08
MT alone	123/431	1.00 (reference)		1.85 (1.25-2.73)	0.001
Registry	25/162			1.00 (reference)	
6 Months					
PCI+MT	33/440	0.41 (0.28-0.60)	<0.001	0.47 (0.29-0.76)	0.002
MT alone	80/434	1.00 (reference)		1.16 (0.77-1.73)	0.48
Registry	26/163			1.00 (reference)	
12 Months					
PCI+MT	26/437	0.39 (0.25-0.61)	<0.001	0.38 (0.23-0.64)	<0.001
MT alone	65/429	1.00 (reference)		0.96 (0.63-1.47)	0.86
Registry	25/159			1.00 (reference)	
24 Months					
PCI+MT	25/425	0.49 (0.31-0.77)	0.002	0.40 (0.23-0.69)	0.001
MT alone	51/424	1.00 (reference)		0.82 (0.52-1.30)	0.40
Registry	23/157			1.00 (reference)	



# How ICs translate invasive physiology in practice

## Letter to the Editor

**Use and Abuse of IVUS and FFR by Magni V et al. or Why You Shouldn't Believe The Saying, "If You Want to Treat, use IVUS. If You Don't, Use FFR"**

### TO THE EDITOR

I enjoyed reading Drs. Magni, Chieffo, and Colombo's article describing use and abuse of intravascular ultrasound and fractional flow reserve [1]. Although it was not directly stated, I read into the conclusion of both cases the often used but mistaken phrase, "If you want to treat, use IVUS; if you don't, use FFR."

ment will correlate with flow mostly in the extreme ranges.

On review of the FFR and IVUS ischemic thresholds, Magni et al. summarize five selected FFR studies (omitting 15 additional studies) and express concern about the small patient numbers, especially and understandably for LM narrowings. Nonetheless, the LM validation studies, while small, produced convincing favorable long term outcomes. The recent FAME study [2] using an FFR threshold of 0.80 at the upper limit of the gray zone (0.75–0.80) demonstrated significantly better clinical outcomes when compared with angiography alone for multivessel PCI lesion selection. In specific and unusual clinical circumstances (e.g., ACS), knowledge of FFR and ischemia is more limited. For these cases, I agree caution is needed. None-

2021



$$\frac{\text{Invasive Assessment}}{\text{Coronary Angiograms}} = \frac{16.287}{280.604} = 5.8\%$$





# The #FullPhysiology group









# Why Full Physiology?





# F. Ph. For Structural and Functional abn.





Courtesy from T. Engstroem

Crea F, et al. *Eur Heart J* 2016;37:1514-6



# Different indexes for different compartments?



Nico H.J. Pijls, *Circulation*. 2001;104:2003-2006  
Fearon et al. *Circulation*. 2003;107:3129-3132





# Our Ach protocol

- 1 vial of Miovisin 20mg/2ml diluted in 100 ml of NaCl 0.9%
- 1 ml of this solution (200 mcg/ml) diluted with 19 ml of 0.9% NaCl = 20 ml of 10 mcg/ml Ach (Master solution)
- Take from the Master solution:
  - 2 ml + 18 ml of 0.9% NaCl % (20 mcg)
  - 5ml + 15 ml of 0.9% NaCl % (50 mcg)
  - 10 ml + 10 ml of 0.9% NaCl % (100 mcg)
  - 20 ml (200 mcg)
- infuse manually in the LCA incremental doses of Ach (20-50-100-200 mg) in 2 minutes  
(rarely we infuse incremental doses of Ach 20-50-80 mg in the RCA)



• Esiti Area PreAutorizzazione CTS 17, 18 e 19 Marzo 2021

Richieste di inserimento nell'elenco istituito ai sensi della Legge n.648/96

6. Inserimento del medicinale Acetilcolina cloruro (Miovisin), per via intracoronarica, nell'elenco istituito ai sensi della Legge n. 648/96 come test farmacologico per la valutazione delle disfunzioni vascolari coronariche.

**Parere CTS:** La CTS esprime parere non favorevole.

Off label




# Why perform a comprehensive assessment?


1. To make a correct and complete diagnosis
2. To guide a specific treatment
3. To assess prognosis




# CAD and NOCAD are both clinically relevant





Patel NEJM 2010



Dati GISE 2021



Shaw Circ 2006



Taqueti JACC 2018



# What is #FullPhysiology assessment

1

## Epicardial disease assessment

- NHPR ( $\leq 0.89$ )
- cFFR ( $\leq 0.83$ )
- FFR ( $\leq 0.80$ ) -> perform pullback



2

## Microvascular disease assessment

- IMR ( $> 25$ )
- CFR ( $< 2.0$ )
- RRR ( $< 2.0$ )\*


$$\text{*Resistive resistance ratio} = \frac{Trm \cdot Pdr}{Thm \cdot Pdh}$$



3

## Vasomotor testing

- Ach



4

## Post PCI Full Physiology assessment if applicable

- NHPR/cFFR/IMR/CFR/FFR -> perform pullback







# Epicardial disease assessment

$Pd/Pa$



$RFR$



$cFFR$




$FFR$





# Epicardial disease assessment


## *The importance of pullback*





# Epicardial disease assessment

- Functional mapping can discriminate better mixed patterns
- Diffuse disease is associated with longer stents and myocardial injury
- PPG index is currently tested in a multicenter study






# What is #FullPhysiology assessment

1

## Epicardial disease assessment

- NHPR ( $\leq 0.89$ )
- cFFR ( $\leq 0.83$ )
- FFR ( $\leq 0.80$ ) -> perform pullback



2

## Microvascular disease assessment

- IMR ( $> 25$ )
- CFR ( $< 2.0$ )
- RRR ( $< 2.0$ )\*


$$*Resistive\ resistance\ ratio = \frac{Trm \cdot Pdr}{Thm \cdot Pdh}$$



3

## Vasomotor testing

- Ach



4

## Post PCI Full Physiology assessment if applicable


- NHPR/cFFR/IMR/CFR/FFR -> perform pullback








# CORMICA trial: efficacy of a tailored approach



Ford JACC 2018

# Importance of microcirculation

In 313 patients with FFR>0.80, those with low CFR and high IMR (microvascular dysfunction) had significantly higher rate of death, MI, or revascularization.





Lee JM, *et al.* Journal of the American College of Cardiology 2016.



# Index of microcirculatory resistance

## IMR in Comparison with Cardiac MR




Collet CRT 2022  
Vandelloo Eurointervention 2022





# Two types of CMD. Both are bad




Mechanism	Systemic Vasculature			Myocardium		
	Nitric Oxide Synthase Activity	Acetylcholine Dilatation	Exercise Blood Pressure	NT-proBNP	Exercise Coronary Perfusion Efficiency	Inducible Ischemia
Reference Group (n = 40)	 High vascular tone at rest → Low vascular tone at stress	Normal	Normal	34 pgml <sup>-1</sup>	65%	22%
Functional CMD (n = 28)	 Low vascular tone at rest → Low vascular tone at stress	Increased ↑↑	Normal	69 pgml <sup>-1</sup>	46%	77%
Structural CMD (n = 18)	 High vascular tone at rest → High vascular tone at stress	Increased ↑	Reduced ↓	132 pgml <sup>-1</sup>	41%	88%

Rahman H et al. JACC 2020;75:2538–2549.






# CORMICA trial: efficacy of a tailored approach




CorMICA


Primary endpoint: SAQ




Illness Perception



EQ5D



Treatment Satisfaction



CB. 16.11.2019

Ford JACC 2018



# ESC guidelines for CCS

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Guidewire-based CFR and/or microcirculatory resistance measurements <u>should be considered in patients with persistent symptoms, but coronary arteries that are either angiographically normal or have moderate stenoses with preserved iwFR/FFR.</u> <sup>412,413</sup>	<b>IIa</b>	<b>B</b>
Intracoronary acetylcholine with ECG monitoring <u>may be considered during angiography, if coronary arteries are either angiographically normal or have moderate stenoses with preserved iwFR/FFR, to assess microvascular vasospasm.</u> <sup>412,438–440</sup>	<b>IIb</b>	<b>B</b>
Transthoracic Doppler of the LAD, CMR, and PET may be considered for non-invasive assessment of CFR. <sup>430–432,441</sup>	<b>IIb</b>	<b>B</b>

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
An ECG is recommended during angina if possible.	<b>I</b>	<b>C</b>
Invasive angiography or coronary CTA is recommended in patients with characteristic episodic resting angina and ST-segment changes, which resolve with nitrates and/or calcium antagonists, to determine the extent of underlying coronary disease.	<b>I</b>	<b>C</b>
Ambulatory ST-segment monitoring should be considered to identify ST-segment deviation in the absence of increased heart rate.	<b>IIa</b>	<b>C</b>
An intracoronary provocation <u>test should be considered to identify coronary spasm in patients with normal findings or non-obstructive lesions on coronary arteriography and a clinical picture of coronary spasm, to diagnose the site and mode of spasm.</u> <sup>412,414,438–440</sup>	<b>IIa</b>	<b>B</b>




# What is #FullPhysiology assessment

1

## Epicardial disease assessment

- NHPR ( $\leq 0.89$ )
- cFFR ( $\leq 0.83$ )
- FFR ( $\leq 0.80$ ) -> perform pullback



2

## Microvascular disease assessment

- IMR ( $> 25$ )
- CFR ( $< 2.0$ )
- RRR ( $< 2.0$ )\*


$$\text{*Resistive resistance ratio} = \frac{Trm \cdot Pdr}{Thm \cdot Pdh}$$



3

## Vasomotor testing


- Ach




4

## Post PCI Full Physiology assessment if applicable

- NHPR/cFFR/IMR/CFR/FFR -> perform pullback









# CCS: a continuum of Angina Endotypes

## 1. Obstructive Epicardial CAD

NHPR  $\leq 0.89$  and/or cFFR  $\leq 0.83$  and/or FFR  $\leq 0.80$

## 2. Microvascular angina

Structural: IMR  $> 25$

Functional\*: MV spasm: angina + ST changes and no epicardial spasm (+  $\uparrow$  Tmn)  
CFR  $< 2.0$  (+ FFR  $> 0.80$  and IMR  $\leq 25$ )

## 3. Vasospastic angina

angina + ST changes and  $> 90\%$  epicardial spasm


## 4. Mixed Angina

combination of 1, 2 and 3

## 5. Non cardiac pain

exclusion of 1-2-3

\*Selective MV dysfunction: RRR  $< 2.0$  (+ IMR  $\leq 25$ )




Kunadian EHJ 2020 (mod)




# Empiric use of CCB: the EDIT-CMD trial



Primary Endpoint  
No Additional Effect of Diltiazem in Treatment Success



No Effect in Improvement in Angina and Quality of Life



No Improvement in Coronary Function Test Results








# What is #FullPhysiology assessment

1

## Epicardial disease assessment

- NHPR ( $\leq 0.89$ )
- cFFR ( $\leq 0.83$ )
- FFR ( $\leq 0.80$ ) -> perform pullback



2

## Microvascular disease assessment

- IMR ( $> 25$ )
- CFR ( $< 2.0$ )
- RRR ( $< 2.0$ )\*


$$\text{*Resistive resistance ratio} = \frac{Trm \cdot Pdr}{Thm \cdot Pdh}$$



3

## Vasomotor testing


- Ach



4

## Post PCI Full Physiology assessment if applicable

- NHPR/cFFR/IMR/CFR/FFR -> perform pullback






# Importance of post PCI physiology

## Study flow-chart

PROPHET-FFR  
Study




Leone LBT EuroPCR 2022  
Leone Frontiers Cardiovasc Med 2022




# Importance of post PCI physiology

PROPHET-FFR  
Study

Post – PCI Physiological results (Group 3)



\*  
vs 0.76±0.03 in group 2 (p NS)




Leone LBT EuroPCR 2022  
Leone Frontiers Cardiovasc Med 2022







# Importance of post PCI physiology

## PROPHET-FFR Study



21 months (IQR 14-32)



Leone LBT EuroPCR 2022  
Leone Frontiers Cardiovasc Med 2022



# Conclusions

- We have relatively simple tools to comprehensively assess coronary circulation
- A correct diagnosis can have important therapeutic and prognostic implications
- INOCA has an important socio-economic impact and now can be treated appropriately only using an invasive guide using a pressure/thermodilution wire
- Comprehensive functional assessment for INOCA can represent a useful approach also for a variety of other clinical settings



#Grazi  
e





